Skip to main content
Loading ResearchHub…
Correction: Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in patients with moderate-to-severe chronic spontaneous urticaria with inadequat | ResearchHub